Denmark · Delayed Price · Currency is DKK Bavarian Nordic Company Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.
It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Country | Denmark |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,906 |
| CEO | Tarja Stenvall |
Contact Details
Address: Philip Heymans Alle 3 Hellerup, 2900 Denmark | |
| Phone | 45 33 26 83 83 |
| Website | bavarian-nordic.com |
Stock Details
| Ticker Symbol | BAVA |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0015998017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Russell Thirsk M.Sc. | Executive Vice President and Chief Operating Officer |